Skip to main content

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of FMC Corporation (FMC) Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased FMC Corporation (“FMC” or the “Company”) (NYSE: FMC) common stock between November 1, 2022 and October 30, 2023, inclusive (the “Class Period”). FMC investors have until January 8, 2024 to file a lead plaintiff motion.

Investors suffering losses on their FMC investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On July 10, 2023, before market hours, FMC disclosed that it was cutting its revenue guidance for the second quarter and the 2023 fiscal year due to “substantially lower-than-expected volumes due to an abrupt and significant reduction in inventory by channel partners.” On this news, FMC’s stock price fell $11.62, or 11.1%, to close at $92.63 per share on July 10, 2023, thereby injuring investors.

Then, on September 7, 2023, Blue Orca Capital published a report alleging that FMC had made false statements regarding the status of patent protections for its flagship products following legal defeats in multiple countries and that “contrary to the Company’s claims, FMC’s process patents do not protect its flagship product from generic competition.” On this news, FMC’s stock price fell $6.04, or 7.4%, to close at $75.43 per share on September 7, 2023.

Then, on October 23, 2023, FMC announced that it was again lowering its revenue guidance for the third and fourth quarters of 2023 as well as for the full year 2024, projecting earnings well below analyst expectations. On this news, FMC’s stock price fell $8.83, or 12.2%, to close at $58.12 per share on October 23, 2023, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the diminishment of patent protection for FMC’s flagship products following legal defeats in key markets including India, China, and Brazil had opened the door to increased competition from generics; (2) the Company repeatedly mislead investors about the status of such proceedings and falsely claimed that it did not and would not face generic competition in key markets until 2026 at the earliest; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased FMC common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.